Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism HIV-1 pol inhibitors(Human immunodeficiency virus type 1 Pol protein inhibitors), NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC37H48N6O5S2 |
InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N |
CAS Registry155213-67-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C | Phase 3 | - | - | |
Chronic hepatitis C genotype 1 | Phase 2 | United States | 01 Apr 2013 | |
Chronic hepatitis C genotype 1 | Phase 2 | Taiwan Province | 01 Apr 2013 | |
Chronic hepatitis C genotype 1 | Phase 2 | Thailand | 01 Apr 2013 | |
Fibrosis | Phase 2 | United States | 01 Apr 2013 | |
Fibrosis | Phase 2 | Taiwan Province | 01 Apr 2013 | |
Fibrosis | Phase 2 | Thailand | 01 Apr 2013 |